This is a double-blind, placebo controlled study for subjects that have either failed previous interferon therapy or relapsed after completion ofinterferon therapy for chronic hepatitis C. Subjects will be randomized to either Intron A 3 MU daily or Intron A 5 MU daily, plus ribavirin 1000-1200 mg/day or placebo. All subjects will receive up to 48 weeks of therapy, and will have an additional 24 weeks of follow up.
Showing the most recent 10 out of 563 publications